Siga Shouldn’t Have to Pay PharmAthene Over Drug, Lawyer Says

Siga Technologies Inc. (SIGA) shouldn’t have to hand over 50 percent of the profits from a smallpox medicine to rival PharmAthene Inc. (PIP), lawyers for the drugmaker told an appeals court today.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at pmilford@bloomberg.net

To contact the editor responsible for this story: Andrew Dunn at adunn8@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.